Solos Endoscopy, Inc. Breast Endoscopy System Featured in July/August Issue of The Breast Journal

Jun 24, 2010, 10:30 ET from Solos Endoscopy, Inc.

BOSTON, June 24 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company's Breast Endoscopy System, the MammoView®, will be featured in a full-page advertisement in the July/August issue of The Breast Journal. The publication, founded in 1994, is circulated bi-monthly to nearly 2,500 specialist surgeons throughout the United States.

The Breast Journal is the first comprehensive, multidisciplinary source devoted exclusively to all facets of research, diagnosis, and treatment of breast disease. The Breast Journal encompasses the latest news and technologies from the many medical specialties concerned with breast disease care in order to address the disease within the context of a woman's total health. This editorial philosophy recognizes the special social, sexual, and psychological considerations that distinguish cancer and breast cancer in particular, from other serious diseases. According to the National Cancer Institute, it is estimated that there will be 209,060 new cases and 40,230 deaths from breast cancer in the United States in 2010.

"Solos Endoscopy is pleased to have its MammoView's instrument line displayed in one of the industry's top publications. The advertisement is geared towards increasing the exposure of our entire Solos Endoscopy instrument line to potential customers and partners," stated Bob Segersten, President of Solos Endoscopy, Inc.

Throughout the remainder of 2010, the Company will continue its new product development for the MammoView® product line as well as market expansion through its efforts to meet the requirements of the ISO 13485 standard and ultimately obtain the CE Mark and the permission to sell medical devices in the European Union and Canada.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at:

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SOURCE Solos Endoscopy, Inc.